Achieved 16% full-year revenue growth and record fourth-quarter results despite undergoing a fundamental rebuild of the commercial organization.

Attributed performance to strong European business adoption and continued momentum in IHR, LPR, and LiquiFix product lines.

Implemented a 'deep and narrow' geographic strategy, shifting from wide distribution to concentrated density in high-volume institutions to cultivate multiple users per site.

Upgraded the sales talent profile, prioritizing high intellect and clinical acumen over legacy soft tissue experience, with 40% of the force hired in the last six months.

Transitioned the hernia business mix from 70% ventral to 50%, with significant growth in inguinal and hiatal procedures driven by robotic surgery adoption.

Maintained operating discipline and improved leverage, utilizing savings to fund increased customer education and training events.

Anticipates full-year 2026 revenue growth of at least 8%, adopting a prudent stance to account for the 'change curve' of a restructured sales force.

Expects a typical seasonal revenue cadence with a more pronounced step-up in the second half as the newest sales cohorts reach productivity inflection points.

Plans a full market launch of a long-term resorbable OviTex product on April 1, 2026, to compete directly with biosynthetic alternatives like Phasix.

Focuses 2026 on 'contract execution,' shifting from signing new GPO/IDN agreements to translating existing signatures into active clinical usage and revenue.

Aims to expand the European presence into Continental markets and introduce the PRS portfolio OUS by late 2026 or early 2027.

Restructured U.S. commercial leadership by implementing a General Manager structure to bring decision-making closer to local customers.

Identified Q1 headwinds including severe January weather impacting elective procedures and temporary disruption from splitting sales territories.

Noted that while unit growth remains high (22% in hernia), ASPs are impacted by a mix shift toward smaller units used in robotic and laparoscopic procedures.

Upsized the debt facility and raised equity capital in late 2025 to ensure financial flexibility during the commercial transition.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management cited the 'wholesale change' across the organization and the 6-9 month ramp-up period for the 40% of reps who are new to the company.

The guidance accounts for contracting complexity, where implementation timelines vary significantly across different hospital systems.

The company is de-emphasizing 'hinterland' hospitals to focus on high-density academic hubs and urban centers.

This shift involves splitting territories, which creates a temporary transition phase as accounts are reassigned and new relationships are established.

Unit growth is expected to remain robust as the portfolio aligns with the global trend toward robotic surgery, which utilizes smaller, lower-ASP mesh pieces.

Management emphasized that the shift toward smaller-sized units does not negatively impact gross margins, which improved due to lower excess and obsolete inventory expenses.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.